Chronic treatment with anti-bipolar drugs suppresses glutamate release from astroglial cultures

Amino Acids

Volumn 47, Issue 5, 2015, Pages 1045-1051

  Liu, Zhuo ^a   Song, Dan ^a   Yan, Enzhi ^a   Verkhratsky, Alexei ^b,c,d   Peng, Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD   (Russian Federation)

Author keywords

Astroglia; Bipolar disorder; Carbamazepine; Glutamate; Lithium; Mood disorders; Neuropsychiatric diseases; Valproic acid

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID RECEPTOR BLOCKING AGENT; CALCIUM; CARBAMAZEPINE; GLUTAMIC ACID; LITHIUM CARBONATE; POTASSIUM CHLORIDE; TRANQUILIZER; VALPROIC ACID;

ANIMAL; ASTROCYTE; CYTOLOGY; DRUG EFFECTS; ENDOPLASMIC RETICULUM; HUMAN; METABOLISM; MOUSE; PRIMARY CELL CULTURE; TRANSPORT AT THE CELLULAR LEVEL;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIMANIC AGENTS; ASTROCYTES; BIOLOGICAL TRANSPORT; CALCIUM; CARBAMAZEPINE; ENDOPLASMIC RETICULUM; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; LITHIUM CARBONATE; MICE; POTASSIUM CHLORIDE; PRIMARY CELL CULTURE; VALPROIC ACID;

EID: 84939945811     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-015-1936-y     Document Type: Article

References (42)

1. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B (2015) Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res 161(1):4-18
2. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, Cohen BM, Pope HG Jr, Renshaw PF, Ongur D (2010) Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 35(3):834-846
3. Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81(2):229-248
4. Chen G, Henter ID, Manji HK (2010) Presynaptic glutamatergic dysfunction in bipolar disorder. Biol Psychiatry 67(11):1007-1009
5. Czeh B, Fuchs E, Flugge G (2013) Altered glial plasticity in animal models for mood disorders. Curr Drug Targets 14(11):1249-1261
6. Eastwood SL, Harrison PJ (2010) Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 67(11):1010-1016
7. Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A (2007) Glia: the fulcrum of brain diseases. Cell Death Differ 14(7):1324-1335
8. Golovina VA (2005) Visualization of localized store-operated calcium entry in mouse astrocytes. Close proximity to the endoplasmic reticulum. J Physiol 564(Pt 3):737-749
9. Hertz L (2012) Isotope-based quantitation of uptake, release, and metabolism of glutamate and glucose in cultured astrocytes. Methods Mol Biol 814:305-323
10. Hertz L, Peng L, Lai JC (1998) Functional studies in cultured astrocytes. Methods 16(3):293-310
11. Jeremic A, Jeftinija K, Stevanovic J, Glavaski A, Jeftinija S (2001) ATP stimulates calcium-dependent glutamate release from cultured astrocytes. J Neurochem 77(2):664-675
12. Kirischuk S, Parpura V, Verkhratsky A (2012) Sodium dynamics: another key to astroglial excitability? Trends Neurosci 35(8):497-506
13. 2 gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific. Psychopharmacology 194(3):333-345
14. Li B, Zhang S, Li M, Zhang H, Hertz L, Peng L (2009) Down-regulation of GluK2 kainate receptor expression by chronic treatment with mood-stabilizing anti-convulsants or lithium in cultured astrocytes and brain, but not in neurons. Neuropharmacology 57(4):375-385
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265-275
16. 2+ dynamics and consequent glutamate release from rat astrocytes. Glia 56(8):821-835
17. Martineau M, Parpura V, Mothet JP (2014) Cell-type specific mechanisms of d-serine uptake and release in the brain. Front Synaptic Neurosci 6:12
18. Michael N, Erfurth A, Ohrmann P, Gossling M, Arolt V, Heindel W, Pfleiderer B (2003) Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology 168(3):344-346
19. Miguel-Hidalgo JJ, Waltzer R, Whittom AA, Austin MC, Rajkowska G, Stockmeier CA (2010) Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord 127(1-3):230-240
20. Ongur D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95(22):13290-13295
21. Ongur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, Renshaw PF (2008) Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 64(8):718-726
22. Parpura V, Zorec R (2010) Gliotransmission: exocytotic release from astrocytes. Brain Res Rev 63(1-2):83-92
23. Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG (1994) Glutamate-mediated astrocyte-neuron signalling. Nature 369(6483):744-747
24. 2+ sources for the exocytotic release of glutamate from astrocytes. Biochim Biophys Acta 1813(5):984-991
25. Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, Stout RF Jr, Spray DC, Reichenbach A, Pannicke T, Pekny M, Pekna M, Zorec R, Verkhratsky A (2012) Glial cells in (patho)physiology. J Neurochem 121(1):4-27
26. Pekny M, Pekna M (2004) Astrocyte intermediate filaments in CNS pathologies and regeneration. J Pathol 204(4):428-437
27. Pekny M, Pekna M (2014) Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev 94(4):1077-1098
28. Pekny M, Wilhelmsson U, Pekna M (2014) The dual role of astrocyte activation and reactive gliosis. Neurosci Lett 565:30-38
29. Peng LA, Juurlink BH, Hertz L (1991) Differences in transmitter release, morphology, and ischemia-induced cell injury between cerebellar granule cell cultures developing in the presence and in the absence of a depolarizing potassium concentration. Brain Res Dev Brain Res 63(1-2):1-12
30. Rajkowska G (2014) Pathology in astroglia, glutamate, and GABA in major depressive disorder: evidence from studies of human postmortem tissue. In: Popoli M, Diamond D, Sanacora G (eds) Synaptic stress and pathogenesis of neuropsychiatric disorders. Springer Science+Business Media, New York, pp 245-264
31. Rajkowska G, Stockmeier CA (2013) Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 14(11):1225-1236
32. + signalling in astroglia: differential filtering of extracellular cations. Cell Calcium 54(2):120-125
33. Sanacora G, Banasr M (2013) From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry 73(12):1172-1179
34. Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32(12):638-647
35. +) and in energy consumption rates in astrocytes. Neurochem Res 38(11):2364-2374
36. Verkhratsky A, Krishtal OA, Burnstock G (2009) Purinoceptors on neuroglia. Mol Neurobiol 39(3):190-208
37. Verkhratsky A, Sofroniew MV, Messing A, deLanerolle NC, Rempe D, Rodriguez JJ, Nedergaard M (2012) Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 4(3):e00082
38. Verkhratsky A, Rodriguez JJ, Steardo L (2013) Astrogliopathology: a central element of neuropsychiatric diseases? Neuroscientist 20(6):576-588
39. Verkhratsky A, Marutle A, Rodriguez-Arellano JJ, Nordberg A (2014a) Glial asthenia and functional paralysis: a new perspective on neurodegeneration and Alzheimer's Disease. Neuroscientist. doi: 10.1177/1073858414547132
40. Verkhratsky A, Reyes RC, Parpura V (2014b) TRP channels coordinate ion signalling in astroglia. Rev Physiol Biochem Pharmacol 166:1-22
41. i and its reduction by anti-bipolar drugs in cultured astrocytes combined with its mRNA expression in freshly isolated cells support the importance of astrocytic L-channels. Cell Calcium 54(5):335-342
42. Zarate CA Jr, Manji HK (2008) Bipolar disorder: candidate drug targets. Mt Sinai J Med 75(3):226-247